Dark Forest Capital Management LP Grows Stock Holdings in Boston Scientific Corporation $BSX

Key Points

• Dark Forest Capital Management LP increased its holdings in Boston Scientific Corporation by 255.4%, acquiring an additional 46,232 shares, bringing its total to 64,332 shares valued at approximately $6.49 million.
• Several institutional investors have also recently bought or increased their shares in Boston Scientific, contributing to a total institutional ownership of 89.07% of the company's stock.
• Boston Scientific reported a 22.8% year-over-year revenue increase, achieving $5.06 billion during the last quarter, and surpassed EPS expectations by $0.03.

Dark Forest Capital Management LP lifted its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 255.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 64,332 shares of the medical equipment provider's stock after acquiring an additional 46,232 shares during the quarter. Dark Forest Capital Management LP's holdings in Boston Scientific were worth $6,490,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its holdings in Boston Scientific by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider's stock valued at $13,577,311,000 after buying an additional 1,697,945 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its holdings in Boston Scientific by 2.5% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 22,312,967 shares of the medical equipment provider's stock valued at $1,992,994,000 after buying an additional 554,388 shares in the last quarter. Invesco Ltd. lifted its holdings in Boston Scientific by 5.3% during the 1st quarter. Invesco Ltd. now owns 16,624,940 shares of the medical equipment provider's stock valued at $1,677,124,000 after buying an additional 834,274 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in Boston Scientific by 10.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider's stock valued at $1,426,779,000 after buying an additional 1,383,524 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Boston Scientific by 18.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 10,839,362 shares of the medical equipment provider's stock valued at $968,172,000 after buying an additional 1,709,461 shares in the last quarter. Institutional investors own 89.07% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on BSX. Leerink Partnrs upgraded shares of Boston Scientific to a "strong-buy" rating in a report on Monday, June 16th. Barclays boosted their price target on shares of Boston Scientific from $125.00 to $133.00 and gave the company an "overweight" rating in a report on Thursday, July 24th. Royal Bank Of Canada restated an "outperform" rating on shares of Boston Scientific in a report on Thursday, July 24th. Needham & Company LLC restated a "buy" rating and issued a $115.00 price target on shares of Boston Scientific in a report on Wednesday, May 28th. Finally, Leerink Partners assumed coverage on shares of Boston Scientific in a report on Monday, June 16th. They issued an "outperform" rating and a $118.00 price target for the company. Three research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $117.50.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business's stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $105.43, for a total transaction of $5,271,500.00. Following the sale, the executive vice president owned 178,342 shares of the company's stock, valued at approximately $18,802,597.06. The trade was a 21.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Edward J. Ludwig sold 4,000 shares of the business's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the sale, the director directly owned 18,479 shares in the company, valued at approximately $1,959,328.37. This represents a 17.79% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 174,214 shares of company stock worth $18,397,457 in the last quarter. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Stock Down 0.1%

Shares of NYSE BSX traded down $0.15 during trading hours on Friday, hitting $107.14. 4,062,436 shares of the stock were exchanged, compared to its average volume of 5,787,252. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The company has a market cap of $158.76 billion, a PE ratio of 63.78, a PEG ratio of 2.58 and a beta of 0.65. The firm has a fifty day moving average price of $104.77 and a 200-day moving average price of $102.20. Boston Scientific Corporation has a 12 month low of $80.64 and a 12 month high of $108.94.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. The firm had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. Boston Scientific's revenue was up 22.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, sell-side analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.